Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. Objective: To determine whether high-risk RET mutations are more aggressive. Design: Retrospective cohort study using institutional multiple endocrine neoplasia type 2 registry. Setting: Tertiary cancer care center. Patients: Patients with MTC and moderate- or high-risk germline RET mutation. Intervention: None (observational study). Main Outcome Measures: Proxies for aggressiveness were overall survival (OS) and time to distant metastatic disease (DMD). Results: A total of 127 moderate-risk and 135 high-risk patients were included (n = 262). Median age at diagnosis was 42.3 years (range, 6.4 to 86.4 years; mean, 41.6 years) for moderate-risk mutations and 23.0 years (range, 3.7 to 66.8 years; mean, 25.6 years) for high-risk mutations (P < 0.0001). Moderate-risk patients had more T3/T4 tumors at diagnosis (P = 0.03), but there was no significant difference for N or M stage and no significant difference in OS (P = 0.40). From multivariable analysis for OS, increasing age [hazard ratio (HR), 1.05/y; 95% confidence interval (CI), 1.03 to 1.08], T3/T4 tumor (HR, 2.73; 95% CI, 1.22 to 6.11), and M1 status at diagnosis (HR, 3.93; 95% CI, 1.61 to 9.59) were significantly associated with worse OS but high-risk mutation was not (P = 0.40). No significant difference was observed for development of DMD (P = 0.33). From multivariable analysis for DMD, only N1 status at diagnosis was significant (HR, 2.10; 95% CI, 1.03 to 4.27). Conclusions: Patients with high- and moderate-risk RET mutations had similar OS and development of DMD after MTC diagnosis and therefore similarly aggressive clinical courses. High-risk connotes increased disease aggressiveness; thus, future guidelines should consider RET mutation classification by disease onset (early vs late) rather than by risk (high vs moderate).
Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. Objective: To determine whether high-risk RET mutations are more aggressive. Design: Retrospective cohort study using institutional multiple endocrine neoplasia type 2 registry. Setting: Tertiary cancer care center. Patients: Patients with MTC and moderate- or high-risk germline RET mutation. Intervention: None (observational study). Main Outcome Measures: Proxies for aggressiveness were overall survival (OS) and time to distant metastatic disease (DMD). Results: A total of 127 moderate-risk and 135 high-risk patients were included (n = 262). Median age at diagnosis was 42.3 years (range, 6.4 to 86.4 years; mean, 41.6 years) for moderate-risk mutations and 23.0 years (range, 3.7 to 66.8 years; mean, 25.6 years) for high-risk mutations (P < 0.0001). Moderate-risk patients had more T3/T4 tumors at diagnosis (P = 0.03), but there was no significant difference for N or M stage and no significant difference in OS (P = 0.40). From multivariable analysis for OS, increasing age [hazard ratio (HR), 1.05/y; 95% confidence interval (CI), 1.03 to 1.08], T3/T4 tumor (HR, 2.73; 95% CI, 1.22 to 6.11), and M1 status at diagnosis (HR, 3.93; 95% CI, 1.61 to 9.59) were significantly associated with worse OS but high-risk mutation was not (P = 0.40). No significant difference was observed for development of DMD (P = 0.33). From multivariable analysis for DMD, only N1 status at diagnosis was significant (HR, 2.10; 95% CI, 1.03 to 4.27). Conclusions: Patients with high- and moderate-risk RET mutations had similar OS and development of DMD after MTC diagnosis and therefore similarly aggressive clinical courses. High-risk connotes increased disease aggressiveness; thus, future guidelines should consider RET mutation classification by disease onset (early vs late) rather than by risk (high vs moderate).
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: D Zenaty; Y Aigrain; M Peuchmaur; P Philippe-Chomette; C Baumann; F Cornelis; J P Hugot; D Chevenne; V Barbu; P J Guillausseau; M Schlumberger; J C Carel; J P Travagli; J Léger Journal: Eur J Endocrinol Date: 2009-02-24 Impact factor: 6.664
Authors: Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch Journal: Ann Surg Oncol Date: 2019-09-23 Impact factor: 5.344
Authors: Giovanni Innella; Cesare Rossi; Maria Romagnoli; Andrea Repaci; Davide Bianchi; Maria Elena Cantarini; Davide Martorana; Lea Godino; Andrea Pession; Antonio Percesepe; Uberto Pagotto; Daniela Turchetti Journal: Cancers (Basel) Date: 2020-11-05 Impact factor: 6.639
Authors: P Fanis; N Skordis; S Frangos; G Christopoulos; E Spanou-Aristidou; E Andreou; P Manoli; M Mavrommatis; S Nicolaou; M Kleanthous; M A Cariolou; V Christophidou-Anastasiadou; G A Tanteles; L A Phylactou; V Neocleous Journal: J Endocrinol Invest Date: 2018-02-02 Impact factor: 4.256
Authors: Arezou A Ghazani; Katelyn M Breen; Meaghan Dwan; Justine A Barletta; Donna R Vatnick; Samantha M Stokes; Caroline Block; Gerard M Doherty; Aviva Y Cohn; Ellen Marqusee; Judy E Garber; Huma Q Rana Journal: Am J Case Rep Date: 2020-12-27